Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose beta2-agonists and physical performance in healthy males
2012-002804-42Phase 4Terminated
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of salbutamol and terbutaline, sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Muscle strength, Sprint ability and 1 more. Started Sep 2012; status: terminated.
02
Drugs
salbutamolterbutaline
Beyond the preview
Go deeper on 2012-002804-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002804-42.